NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Capital Expenditures of -$38000.0 for Q4 2024, down 3700.0% quarter-over-quarter from -$1000.0 in Q3 2024.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Capital Expenditures for 3 consecutive years, with -$38000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Capital Expenditures changed N/A year-over-year to -$38000.0; the TTM figure through Dec 2025 stood at -$39000.0 (down 103.2% YoY), while the FY2025 annual figure was -$7000.0, up 85.42% from the prior year.
- Capital Expenditures declined to -$38000.0 in Q4 2024 per NBP's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.9 million in Q4 2020 and bottomed at -$668360.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -152,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Dec 31, 2020 | -489,950.53 |
| Sep 30, 2020 | -668,359.95 |
| Dec 31, 2019 | -1.08 Mn |